Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Here’s What Happened

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped up prior to trading on Thursday. The stock had previously closed at $8.77, but opened at $9.53. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.10, with a volume of 1,562 shares.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 3.5%

The company’s 50 day moving average price is $9.06 and its two-hundred day moving average price is $9.28. The firm has a market cap of $15.45 billion, a PE ratio of 9.08, a P/E/G ratio of 3.16 and a beta of 0.08. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. As a group, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.